Advertisement
News
Advertisement

Millennium Research Group to Release Their Latest US Clot Management Data

Tue, 12/07/2010 - 8:33am
Bio-Medicine.Org

TORONTO, Dec. 7, 2010 /PRNewswire/ -- Millennium Research Group (MRG), the global authority on medical technology market intelligence, will soon release their latest data on the US clot management device market.  

MRG's US Markets for Clot Management Devices 2011 report provides important insight into the device-based treatments of deep vein thrombosis and the complex competitive dynamics of medical device manufacturers in this field. The report also provides market analyses for devices that treat arteriovenous, peripheral artery, coronary, and neurovascular thrombosis, including five-year forecasts, up-to-date market shares, and in-depth qualitative insights.  Market analysis is provided for product segments including thrombectomy devices, thrombolytic infusion catheters, inferior vena cava filters, and neurovascular embolectomy devices.  

"We were able to leverage the results of the physician survey that we conducted this year—Venous Interventions:   The Rise of Venous Stenting and Aggressive Deep-Vein Thrombosis Treatment—to gather additional insight on how physicians expect their use of the different device-based treatments to change over the forecast period," says Stephanie LaBelle, Manager of the Cardiovascular division at MRG.  "A lack of awareness among referring physicians is a major roadblock to increasing the number of interventions in the venous system. However, more facilities are beginning to implement screening processes for high-risk deep-vein thrombosis patients, and awareness of newer treatment options is growing.  The use of pharmacomechanical thrombectomy systems for deep vein thrombosis removal is gaining a lot of attention and, as a result, we expect to see high growth in this segment of the market through 2015."

MRG's clot management device report series also includes coverage of Europe.  Please contact Amy Krohn at 416-364-7776 ext. 101 or

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading